Short-term Intravenous Iron Dextran for IDA

• Status: Not yet recruiting
• Trial end date: 2024-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, randomized, controlled study aims to evaluate the impact of short-term intravenous iron dextran on postoperative recovery and the requirement for allogeneic red blood cells (RBC) transfusion in preoperative Iron-deficiency anemia (IDA) patients receiving orthopedic surgery, thus facilitating developing a simple and effective iron supplement approach for patients' recovery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West China Hospital
• Treatments: Dextrans; Iron; Iron-Dextran Complex

Criteria

Inclusion Criteria:

• Age > 14 years;

• Sign and date the "informed consent form"

Exclusion Criteria:

• Pregnant or lactation;

• Drug abuse, including but not limited to opioids, amphetamines, ice, ketamine, etc.;

• History of anaphylaxis to oral or intravenous iron;

• Nervous system diseases such as peripheral neuropathy, mental illness;

• Other conditions that the investigator deems are not suitable for the study, such as deafness, Parkinson's disease, communication disorders, etc.;

• Participated in other clinical trials during the first three months of the study.